The Know AML website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and Know AML cannot guarantee the accuracy of translated content. Know AML and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Are there clinical trials targeting the NPM1 gene specifically?
Gail Roboz
September 28, 2020
During Blood Cancer Awareness Month, Know AML spoke to Gail Roboz, a world-leading doctor in acute myeloid leukemia. We asked, "Have there been any clinical trials targeting the NPM1 gene specifically?" In this video, Gail describes the importance of NPM1 mutations and how this effects the type of treatment given. She mentions the role of menin inhibitors in early clinical trials for NPM1 mutated acute myeloid leukemia.
To what extent do you agree with the following statements?
Please rate between 1 and 5, with 1 being 'strongly disagree' and 5 being 'strongly agree'.
